Vogler, Sabine (2020): Medicines Pricing: Limitations of Existing Policies and New Models. In: Babar, Zaheer-Ud-Din (ed.): Global Pharmaceutical Policy. Palgrave Macmillan, Singapur, doi.org/10.1007/978-981.

Full text not available from this repository.
Official URL (please open in a new browser tab/window): https://link.springer.com/chapter/10.1007%2F978-98...

Abstract

Medicine price regulation aims to contribute to more affordable access to medicines for both patients and public payers. While there is strong evidence for its achievements, high prices remain a barrier to access, increasingly also in high-income countries. This chapter discusses existing medicine pricing policies, particularly for new medicines, such as external price referencing (EPR), value-based pricing (VBP), tendering and managed entry agreements, with a particular focus on their limitations. New models to address these drawbacks are presented; these include methodological support tools, collaborative approaches and improved transparency.

Item Type: Book Section
Uncontrolled Keywords: Collaboration, Cost-plus pricing, Differential pricing, External price referencing, Health technology assessment, Managed entry agreement, Medicine price, Policy Price regulation, Pricing, Pricing policies, Tendering, Transparency, Value-based pricing
Subjects: OEBIG > Pharmaoekonomie
Date Deposited: 08 Jan 2021 06:52
Last Modified: 06 Apr 2021 17:20
URI: https://jasmin.goeg.at/id/eprint/1545